Clinical and prognostic significances of nuclear and cytoplasmic KIT expressions in extrahepatic bile duct carcinomas

Modern Pathology

Volumn 20, Issue 5, 2007, Pages 562-569

  Hong, Seung Mo ^a   Hwang, Ilseon ^b   Song, Dong Eun ^b   Choi, Jene ^b   Yu, Eunsil ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Carcinoma; Cholangiocarcinoma; Extrahepatic bile duct; KIT expression; Mutation; Nucleus

Indexed keywords

IMATINIB; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER INVASION; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; EXON; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATIONAL ANALYSIS; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TUMOR; UNIVARIATE ANALYSIS; VASCULAR TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CELL NUCLEUS; CYTOPLASM; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; STEM CELL FACTOR; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 34247332346     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800771     Document Type: Article

References (46)

1. Hong SM, Kim MJ, Pi DY, et al. Analysis of extrahepatic bile duct carcinomas according to the New American Joint Committee on Cancer staging system focused on tumor classification problems in 222 patients. Cancer 2005;104:802-810.
2. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human protooncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-3351.
3. Funasaka Y, Boulton T, Cobb M, et al. c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell 1992;3:197-209.
4. Ratajczak MZ, Luger SM, DeRiel K, et al. Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci USA 1992;89:1710-1714.
5. Broxmeyer HE, Maze R, Miyazawa K, et al. The kit receptor and its ligand, steel factor, as regulators of hemopoiesis. Cancer Cells 1991;3:480-487.
6. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
7. Inoue M, Kyo S, Fujita M, et al. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 1994;54:3049-3053.
8. Rajpert-De Meyts E, Skakkebaek NE. Expression of the c-kit protein product in carcinoma-in-situ and invasive testicular germ cell tumours. Int J Androl 1994;17:85-92.
9. Halaban R, Fan B, Ahn J, et al. Growth factors, receptor kinases, and protein tyrosine phosphatases in normal and malignant melanocytes. J Immunother 1992;12:154-161.
10. Cohen PS, Chan JP, Lipkunskaya M, et al. Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood 1994;84:3465-3472.
11. Hines SJ, Organ C, Kornstein MJ, et al. Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 1995;6:769-779.
12. Pietsch T, Nicotra MR, Fraioli R, et al. Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas. Int J Cancer 1998;75:171-175.
13. Elmore LW, Domson K, Moore JR, et al. Expression of c-kit (CD117) in benign and malignant human endometrial epithelium. Arch Pathol Lab Med 2001;125:146-151.
14. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-1703.
15. Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 2001;33:451-455.
16. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-3038.
17. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-1269.
18. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11:728-734.
19. Holcombe RF, Gu M, Imagawa D, et al. Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571). Anticancer Drugs 2003;14:651-657.
20. Hong SM, Kang GH, Lee HY, et al. Smooth muscle distribution in the extrahepatic bile duct: histologic and immunohistochemical studies of 122 cases. Am J Surg Pathol 2000;24:660-667.
21. Hong SM, Cho H, Moskaluk CA, et al. CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. Am J Clin Pathol 2005;124:361-370.
22. Hong SM, Choi J, Ryu K, et al. Promoter hypermethylation of the p16 gene and loss of its protein expression is correlated with tumor progression in extrahepatic bile duct carcinomas. Arch Pathol Lab Med 2006;130:33-38.
23. Watanabe A, Cornelison R, Hostetter G. Tissue microarrays: applications in genomic research. Expert Rev Mol Diagn 2005;5:171-181.
24. Rohr UP, Rehfeld N, Pflugfelder L, et al. Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer 2004;111:259-263.
25. Casali C, Stefani A, Rossi G, et al. The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 2004;77:247-252; discussion 52-53.
26. Scobie JV, Acs G, Bandera CA, et al. C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance. Int J Gynecol Pathol 2003;22:149-155.
27. Micke P, Basrai M, Faldum A, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 2003;9:188-194.
28. Naeem M, Dahiya M, Clark JI, et al. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol 2002;33:1182-1187.
29. Chung CY, Yeh KT, Hsu NC, et al. Expression of c-kit protooncogene in human hepatocellular carcinoma. Cancer Lett 2005;217:231-236.
30. Tsutsui S, Yasuda K, Suzuki K, et al. A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer. Br J Cancer 2006;94:1874-1878.
31. Krams M, Parwaresch R, Sipos B, et al. Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis. Oncogene 2004;23:588-595.
32. Marti U, Burwen SJ, Wells A, et al. Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 1991;13:15-20.
33. Maher PA. Nuclear Translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J Cell Biol 1996;134:529-536.
34. Rakowicz-Szulczynska EM, Herlyn M, Koprowski H. Nerve growth factor receptors in chromatin of melanoma cells, proliferating melanocytes, and colorectal carcinoma cells in vitro. Cancer Res 1988;48:7200-7206.
35. Rakowicz-Szulczynska EM, Rodeck U, Herlyn M, et al. Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors. Proc Natl Acad Sci USA 1986;83:3728-3732.
36. Wang SC, Lien HC, Xia W, et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004;6:251-261.
37. Offterdinger M, Schofer C, Weipoltshammer K, et al. c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol 2002;157:929-939.
38. Ni CY, Murphy MP, Golde TE, et al. Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001;294:2179-2181.
39. Matsuda R, Takahashi T, Nakamura S, et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 1993;142:339-346.
40. Castillo M, Petit A, Mellado B, et al. C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib. J Urol 2004;171:2176-2180.
41. Di Matteo G, Pescarmona E, Peparini N, et al. Histopathological features and clinical course of the gastrointestinal stromal tumors. Hepato-gastroenterology 2002;49:1013-1016.
42. Wang SC, Hung MC. Cytoplasmic/nuclear shuttling and tumor progression. Ann NY Acad Sci 2005;1059:11-15.
43. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001;3:802-808.
44. Lo HW, Xia W, Wei Y, et al. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005;65:338-348.
45. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005;11:5856-5862.
46. Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 2006;59:557-563.